scispace - formally typeset
B

Begonya Comin-Anduix

Researcher at University of California, Los Angeles

Publications -  53
Citations -  4969

Begonya Comin-Anduix is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Melanoma & Immunotherapy. The author has an hindex of 28, co-authored 52 publications receiving 3945 citations. Previous affiliations of Begonya Comin-Anduix include California Institute of Technology & UCLA Medical Center.

Papers
More filters
Journal ArticleDOI

A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells

TL;DR: A microfluidic platform designed for highly multiplexed, reliable, sample-efficient and quantitative measurements of secreted proteins from single cells is reported, which represents a new and informative tool for immune monitoring and clinical assessment.
Journal ArticleDOI

CTLA4 blockade broadens the peripheral T cell receptor repertoire

TL;DR: There was a significant difference in the total unique productive TCR V-beta CDR3 sequences between patients experiencing toxicity with tremelimumab compared with patients without toxicity, representing a pharmacodynamic effect of how this class of antibodies modulates the human immune system.
Journal ArticleDOI

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

TL;DR: Evidence is provided for the molecular and cellular mechanisms that support the rationale for the clinical implementation of antibrain cancer immunotherapies in combination with tumor killing approaches in order to elicit effective antitumor immune responses, and thus, will impact clinical neuro-oncology practice.
Journal ArticleDOI

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Daniel K. Wells, +149 more
- 29 Oct 2020 - 
TL;DR: A model of tumor epitope immunogenicity was developed that filtered out 98% of non-immunogenic peptides with a precision above 0.70 and was validated in an independent cohort of 310 epitopes prioritized from tumor sequencing data and assessed for T cell binding.